CTI BioPharma reports full clinical hold of investigational agent pacritinib
CTI BioPharma announced it received a letter from the FDA notifying the Company that the Company's IND for pacritinib has been placed on full clinical hold. The Company has withdrawn its NDA until the Company has had a chance to review safety and efficacy data from the PERSIST-2 Phase 3 trial. February 09, 2016